In summary, we identified a differential molecular signature with highly recurrent genetic lesions in apoptosis and NF-κB pathways, MYC, and RHOA in EBV+ DLBCL compared with EBV-negative DLBCL. This evidence concerns the gene RHOA and diffuse large B-cell lymphoma.